StockpollyBeta
Get App
Popularity #3,309
KROS · NASDAQ · Biotechnology

Keros Therapeutics (KROS)

Develops protein therapeutics for neuromuscular disease and blood-cell disorders.

$11.70
vs last close−0.03 (−0.26%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue0000032111814000
Cost of revenue100000000000
Gross profit−1000032111814000
434749505956595829302631
Research & development343738414946494420181622
991010101110141012109
General & administrative091010101110141012109
Other expenses000000000000
Operating income−43−46−48−50−59−53152−40−15−29−26−31
465568677422
Other non-operating income−4−6−5−5−6−24−6−7−7−4−2−2
Income before tax−39−40−43−45−53−46158−33−9−25−24−29
Income tax expense00000010−2−1−200
Net income from continuing operations−39−40−43−45−53−46148−31−7−23−24−29
Net income−39−40−43−45−53−46148−31−7−23−24−29
EPS, basic−$1.33−$1.34−$1.46−$1.25−$1.47−$1.14$3.66−$0.76−$0.18−$0.86−$1.21−$1.45
EPS, diluted−$1.33−$1.34−$1.46−$1.25−$1.47−$1.14$3.62−$0.76−$0.18−$0.38−$1.21−$1.45
Weighted average shares, basic303029363640414141272020
Weighted average shares, diluted303029363640414141272020
EBITDA−39−40−43−45−53−29159−33−8−25−23−28
Depreciation & amortization100000000000
EBIT−39−40−43−45−53−29158−33−9−25−24−29